PerkinElmer (NYSE:PKI) issued an update on its first quarter 2021 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $1.29 billion-$1.29 billion, compared to the consensus revenue estimate of $1.19 billion.
Shares of PKI traded down $2.75 during midday trading on Tuesday, hitting $127.81. 1,350,726 shares of the company traded hands, compared to its average volume of 996,559. The firm has a 50 day moving average of $130.77 and a 200-day moving average of $136.41. PerkinElmer has a 52 week low of $88.27 and a 52 week high of $162.70. The stock has a market cap of $14.32 billion, a price-to-earnings ratio of 34.58, a PEG ratio of 0.99 and a beta of 1.19. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.96 and a current ratio of 1.35.
PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Tuesday, February 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.01 by $0.95. PerkinElmer had a net margin of 12.74% and a return on equity of 21.57%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.22 billion. During the same quarter in the prior year, the firm earned $1.35 EPS. The business’s revenue was up 68.2% on a year-over-year basis. Sell-side analysts predict that PerkinElmer will post 7.12 earnings per share for the current fiscal year.
A number of research analysts recently commented on PKI shares. Wells Fargo & Company raised shares of PerkinElmer from an equal weight rating to an overweight rating and increased their price target for the company from $140.00 to $175.00 in a report on Thursday, January 7th. Citigroup increased their price target on shares of PerkinElmer from $150.00 to $155.00 in a report on Wednesday, February 3rd. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $133.93.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.